Sairopa B.V.
- Biotech or pharma, therapeutic R&D
Sairopa is a clinical-stage company that develops novel treatments for cancer by modulating the patient’s immune system. Cancer treatment was revolutionized by the introduction of so-called immune checkpoint inhibitors, that enhances the immune response against the patient’s own tumor. However only about 30% of cancer patients find benefit from such therapies. It is well accepted that for a productive anti-cancer immune response to happen, all elements of the cancer-immunity cycle need to be functional: tumor-antigen release, antigen-processing, -presentation, T-cell activation and blockade of local immunosuppression in the tumor.
Early 2021 Sairopa acquired, backed by Van Herk Investments, a portfolio of therapeutic antibodies. These antibodies were originally developed by BioNovion/Aduro Biotech Europe using the proprietary B-Select antibody platform that was also used to identify pembrolizumab (Keytruda™), BION-1301, and MK-5890 (Guelen et al., 2022)
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}